S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

EU Approves Amneal’s Adcomfo for Severe Allergic Asthma

Adcomfo, a treatment for severe persistent allergic asthma, has received marketing authorization from the European Commission, Amneal Pharmaceuticals said. The decision follows a positive opinion from a European Medicines Agency committee in September.

EU Approves Amneal’s Adcomfo for Severe Allergic Asthma

Developed by Kashiv BioSciences with Alvotech, the add-on treatment is also known as ADL-018/AVT23. Amneal acquired Kashiv in August.

Adcomfo received authorization from the United Kingdom Medicines and Healthcare products Regulatory Agency in March. Amneal said its application for the proposed biosimilar to Novartis’ XOLAIR remains under review in the United States.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!